Abbott (ABT) Q1 FY26 earnings call

Abbott framed Q1 as an on-plan start to a second-half-weighted year, closing the Exact Sciences deal and folding it into a new comparable-growth basis (FY26 sales +6.5–7.5%). Management leaned conservative, explicitly declining to bake a make-up respiratory season into the back half and excluding a potential type-2 non-insulin CGM reimbursement catalyst. The thesis rests on three blocks: sustaining medtech (low-double-digit) and pharma (>7%) momentum, trajectory-change recoveries in core lab diagnostics and Nutrition, and integrating a high-growth cancer-diagnostics franchise. Softer prints in